Company Overview and News

Rift Valley Resources' shares rise following positive results from magnet metals project in Angola

Rift Valley Resources Ltd’s (ASX:RVY) shares are trading about 12% higher intra-day after receiving positive results from geophysical and geological surveys at the Longonjo magnet metals project in Angola.

Rift Valley Resources’ drilling targets large NdPr resource at Angolan project

Rift Valley Resources Ltd (ASX:RVY) has begun a reverse circulation (RC) drilling program targeting a large tonnage, high-grade NdPr resource at the Longonjo project in Angola.

Rift Valley Resources to begin drilling at Longonjo NdPr Project this month

Rift Valley Resources Ltd (ASX:RVY) is making solid progress with preparations for a 9,000-metre drilling campaign that will begin later this month at the Longonjo NdPr Project in Angola.

Rift Valley Resources on track for major NdPr drilling program in Angola

Rift Valley Resources Limited (ASX: RVY) has started field surveys ahead of phase I of a 9,000-metre drilling program as it aims to have the Longonjo project in Angola ranked as one of the world’s largest NdPr projects.

Rift Valley Resources' upcoming drilling program aimed at growing magnet metals resource

Rift Valley Resources Ltd (ASX:RVY) is about to undertake 9,000 metres of drilling at the Longonjo Magnet Metals Project in Angola and has outlined the work to its local administration.

Rift Valley Resources raises $5.5 million in oversubscribed placement

Rift Valley Resources Ltd (ASX:RVY) will issue 366.66 million shares in a share placement priced at 1.5 cents to raise $5.5 million across two tranches.

Rift Valley Resources raising capital to drill Longonjo Magnet Metals Project

Rift Valley Resources Ltd (ASX:RVY) remains focussed on its Longonjo Magnet Metals Project in Angola, and is embarking on a 9,000-metre drilling program.

Rift Valley Resources tapping into growing electric vehicle magnet market

Chairman of Rift Valley Resources (ASX:RVY) Paul Atherley introduces the company to Proactive and discusses their upcoming drill programme at the Longonjo Magnet Metals Project in Angola.

Rift Valley Resources outlines 9,000-metre drill program to grow magnet metals deposit

Rift Valley Resources Ltd (ASX:RVY) has designed a 9,000-metre drill program to evaluate its Longonjo Magnet Metals Project in Angola.

Rift Valley Resources readies for major drilling program at magnet metals project

Rift Valley Resources Ltd (ASX:RVY) is preparing a major drill program aimed at extending mineralisation at the Longonjo NdPr Project in Angola.

Rift Valley Resources appoints new chair to head-up magnet metals strategy

Rift Valley Resources Ltd (ASX:RVY) has appointed accomplished resources executive Paul Atherley as non-executive chairman as it increases its focus on the Longonjo Magnet Metal Project in Angola.

Rift Valley Resources to spin drill to expand magnet metal project

Rift Valley Resources Ltd (ASX:RVY) has commenced field exploration programs for 2018 at its 70% owned Ozango Licence in Angola.

Rift Valley Resources stokes up coffers through gold asset sales to pursue Angola interests

Rift Valley Resources Ltd (ASX: RVY) has executed a conditional sale agreement in relation to its Kitongo Gold Project in Tanzania.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...